Kymriah gets Japanese price tag of $305,800

15 May 2019
kymriah_big

Chuikyo, Japan’s Central Social Insurance Medical Council, on May 15 approved the listing of Swiss pharma giant Novartis’ (NOVN: VX) CAR-T cell therapy Kymriah (tisagenlecleucel) on May 22, with a National Health Insurance (NHI) price tag of some 33.5 million yen ($305,800), according to media reports.

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Kymriah in March this year. Novartis plans to use the one-time personalized therapy in Japan for children and young people with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

Novartis expects peak annual sales of $65.7 million in Japan with up to 216 possible patients, according to a document submitted to the panel.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology